Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR)
OPEN BMJ (Clinical research ed.) | 2 Nov 2018
DS Kessler, SJ MacNeill, D Tallon, G Lewis, TJ Peters, W Hollingworth, J Round, A Burns, CA Chew-Graham, IM Anderson, T Shepherd, J Campbell, CM Dickens, M Carter, C Jenkinson, U Macleod, H Gibson, S Davies and NJ Wiles
To investigate the effectiveness of combining mirtazapine with serotonin-noradrenaline reuptake inhibitor (SNRI) or selective serotonin reuptake inhibitor (SSRI) antidepressants for treatment resistant depression in primary care.
* Data courtesy of Altmetric.com